Anlon Healthcare Limited
Anlon Healthcare Limited (AHCL) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
anlon.in(opens the company website in a new tab)Key metrics
Price as of 2026-09-02
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 33 Cr | 52 Cr | 36 Cr | 51 Cr | 88 Cr |
| Operating expenses (approx.) | 27 Cr | 38 Cr | 23 Cr | 36 Cr | 72 Cr |
| EBITDA | 6 Cr | 14 Cr | 12 Cr | 15 Cr | 16 Cr |
| OPM % | 18.7% | 26.3% | 34.7% | 30.0% | 17.8% |
| Other income | 0.01 Cr | 0.03 Cr | 0.20 Cr | 0.01 Cr | 0.06 Cr |
| Interest | 0.82 Cr | 0.87 Cr | 2 Cr | 0.57 Cr | 0.92 Cr |
| Depreciation | 0.43 Cr | 0.45 Cr | 0.35 Cr | 0.29 Cr | 1 Cr |
| Profit before tax | 5 Cr | 12 Cr | 11 Cr | 14 Cr | 14 Cr |
| Tax % | 29.1% | 25.1% | 51.5% | 23.3% | 39.4% |
| Net profit | 4 Cr | 9 Cr | 5 Cr | 11 Cr | 8 Cr |
| EPS (₹) | ₹2.22 | ₹2.22 | ₹1.13 | ₹2.33 | ₹0.16 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 172 Cr | Sign in for TTM |
| Operating expenses (approx.) | 124 Cr | Sign in for TTM |
| EBITDA | 48 Cr | Sign in for TTM |
| OPM % | 27.6% | Sign in for TTM |
| Other income | 0.26 Cr | Sign in for TTM |
| Interest | 4 Cr | Sign in for TTM |
| Depreciation | 2 Cr | Sign in for TTM |
| Profit before tax | 43 Cr | Sign in for TTM |
| Tax % | 31.6% | Sign in for TTM |
| Net profit | 29 Cr | Sign in for TTM |
| EPS (₹) | ₹6.11 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 53 Cr |
| Reserves | 177 Cr |
| Borrowings | 44 Cr |
| Other liabilities | 76 Cr |
| Total liabilities | 374 Cr |
| Fixed assets (net) | 58 Cr |
| CWIP | — |
| Investments | 0.99 Cr |
| Loans & advances | 0.19 Cr |
| Inventories | 113 Cr |
| Trade receivables | 104 Cr |
| Cash & bank | 4 Cr |
| Other assets | 94 Cr |
| Total assets | 374 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | -79 Cr |
| Cash from investing | -36 Cr |
| Cash from financing | 119 Cr |
| Net cash flow | 3 Cr |
| Free cash flow (OCF − Capex) | -79 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 15.5% |
| ROE % | 11.2% |
| Debtor days | 219 |
| Inventory days | 276 |
| Days payable | 103 |
| Cash conversion cycle | 392 |
| Debt / equity | 0.19 |
| Current ratio | 2.87 |
| Net debt / EBITDA | 0.83 |
Compare with peers
Loading peers…